[
    [
        {
            "time": "2018-01-03",
            "original_text": "Top 4 Marijuana Stocks to Watch",
            "features": {
                "keywords": [
                    "Marijuana",
                    "Stocks",
                    "Watch"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Top 4 Marijuana Stocks to Watch",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-31",
            "original_text": "5 Best Performing Stocks of January",
            "features": {
                "keywords": [
                    "Best",
                    "Performing",
                    "Stocks",
                    "January"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 Best Performing Stocks of January",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-16",
            "original_text": "A Look at Analysts’ Estimates for Johnson & Johnson",
            "features": {
                "keywords": [
                    "Analysts",
                    "Estimates",
                    "Johnson & Johnson"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Look at Analysts’ Estimates for Johnson & Johnson",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-25",
            "original_text": "Will Gilead (GILD) Disappoint Investors in Q4 Earnings?",
            "features": {
                "keywords": [
                    "Gilead",
                    "Disappoint",
                    "Investors",
                    "Q4",
                    "Earnings"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Will Gilead (GILD) Disappoint Investors in Q4 Earnings?",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-23",
            "original_text": "Merck’s 4Q17 Estimates: Animal Health",
            "features": {
                "keywords": [
                    "Merck",
                    "4Q17",
                    "Estimates",
                    "Animal",
                    "Health"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck’s 4Q17 Estimates: Animal Health",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-29",
            "original_text": "Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi",
            "features": {
                "keywords": [
                    "Biotech",
                    "Stock",
                    "AbbVie",
                    "4Q",
                    "Results",
                    "Ablynx",
                    "Sanofi"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-18",
            "original_text": "Wired News – Shire Secured Exclusive Worldwide License to Develop and Commercialize AB Biosciences’ PRIM Program",
            "features": {
                "keywords": [
                    "Shire",
                    "Exclusive",
                    "Worldwide",
                    "License",
                    "Develop",
                    "Commercialize",
                    "AB Biosciences",
                    "PRIM Program"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Wired News – Shire Secured Exclusive Worldwide License to Develop and Commercialize AB Biosciences’ PRIM Program",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-15",
            "original_text": "Cramer Remix: Here are the best-in-show biotechs for 2018...",
            "features": {
                "keywords": [
                    "Cramer",
                    "Remix",
                    "best-in-show",
                    "biotechs",
                    "2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Cramer Remix: Here are the best-in-show biotechs for 2018...",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-22",
            "original_text": "Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far",
            "features": {
                "keywords": [
                    "Cramer",
                    "Remix",
                    "AbbVie",
                    "Biogen",
                    "best-in-show",
                    "biotechs",
                    "2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]